| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Kir7.1 potassium channel. ML418 is a potent, selective blocker of Kir7.1 with an IC50 of 0.31 µM. It also effectively inhibits Kir6.2/SUR1 and exhibits superior selectivity over other Kir channels. Kir7.1 is involved in neurological, cardiovascular, endocrine, and muscle disorders.
|
|---|---|
| ln Vitro |
ML418 exhibits inhibitory activity against Kir7.1 that is dose-dependent, with an IC50 value of 0.31 μM [1]. With IC50 values of 1.3 μM and 1.9 μM, respectively, ML418 exhibits selectivity towards Kir7.1 and Kir6.2/SUR1[1].
ML418 inhibits Kir7.1 with an IC50 value of 0.31 µM (310 nM). It also potently inhibits Kir6.2/SUR1 and exhibits superior selectivity over other Kir channels. The compound is described as the first potent, selective, and CNS-penetrating inhibitor of Kir7.1. |
| ln Vivo |
ML418 (ip; 30 mg/kg) has good CNS distribution, good CNS permeability, and a strong PK impact [1].
Specific in vivo activity data for ML418 are not detailed in the available literature. As a CNS-penetrating Kir7.1 blocker, it can be used for the research of neurological, cardiovascular, endocrine, and muscle disorders. Its ability to cross the blood-brain barrier makes it suitable for studying CNS targets. |
| Enzyme Assay |
In vitro electrophysiological assays for ML418 involve measuring Kir7.1 channel currents using patch-clamp techniques in cells expressing the channel. The compound is applied at various concentrations, and the inhibition of channel current is measured. The IC50 value is determined from the dose-response curve.
|
| Cell Assay |
In vitro cell-based assays for ML418 assess its effects on Kir7.1 channel function in cell lines expressing the channel. Cells are treated with ML418, and potassium flux or membrane potential changes are measured using fluorescent dyes or electrophysiological recordings. The compound's selectivity over other Kir channels can also be assessed.
|
| Animal Protocol |
Animal/Disease Models: Rat and mouse[1]
Doses: 30 mg/kg Route of Administration: intraperitoneal Experimental Results: demonstrated a suitable PK curve (Cmax = 0.20 μM, Tmax = 3 hrs (hrs (hours))) on the central nervous system of mouse brain Systemic permeability is excellent: Kp is 10.9, brain (323.9 ng/g): plasma (29.5 ng/mL). Specific in vivo animal model protocols for ML418 are not described in the available literature. To evaluate its in vivo activity, ML418 could be administered to animal models of neurological, cardiovascular, or metabolic disorders. Endpoints would depend on the specific disease model being studied. |
| ADME/Pharmacokinetics |
Pharmacokinetic data for ML418 indicate that it is CNS-penetrating, suggesting it can cross the blood-brain barrier. As a small molecule, it is expected to have favorable absorption properties. Detailed PK parameters such as half-life and bioavailability are not extensively reported.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for ML418 are not available. As a research compound, its safety profile has not been comprehensively characterized. Toxicity studies would be required to determine its safety margin and potential off-target effects.
|
| References | |
| Additional Infomation |
ML418 is a research tool for studying Kir7.1 potassium channel function. It is the first potent, selective, and CNS-penetrating inhibitor of Kir7.1 and can be used for research on neurological, cardiovascular, endocrine, and muscle disorders. It is not an approved therapeutic agent.
|
| Molecular Formula |
C19H24CLN3O3
|
|---|---|
| Molecular Weight |
377.865163803101
|
| Exact Mass |
377.15
|
| CAS # |
1928763-08-9
|
| Related CAS # |
1928763-08-9;
|
| PubChem CID |
91667465
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
471
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C2=CC=CN=C2C(=C(C=1)CN1CCC(CC1)NC(=O)OC(C)C)O
|
| InChi Key |
CWIXCQOSULUGBT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H24ClN3O3/c1-12(2)26-19(25)22-14-5-8-23(9-6-14)11-13-10-16(20)15-4-3-7-21-17(15)18(13)24/h3-4,7,10,12,14,24H,5-6,8-9,11H2,1-2H3,(H,22,25)
|
| Chemical Name |
iso-Propyl (1-((5-chloro-8-hydroxyquinolin-7-yl)methyl)piperidin-4-yl)carbamate
|
| Synonyms |
ML418 ML-418 ML 418
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~55.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6464 mL | 13.2321 mL | 26.4641 mL | |
| 5 mM | 0.5293 mL | 2.6464 mL | 5.2928 mL | |
| 10 mM | 0.2646 mL | 1.3232 mL | 2.6464 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA